Helix BioPharma Corp.
Research Helix BioPharma Corp. (HBP) on Bullrun: market cap CAD 110.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHBP
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 110.75M
- Financial periodQ1 2026
- Net income-CAD 694.00K
- Free cash flow-CAD 456.00K
Valuation Snapshot
latest market cap is CAD 110.75M.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer;
Frequently asked questions
What is Helix BioPharma Corp.'s market cap?
Helix BioPharma Corp.'s market capitalization is CAD 110.75M.
What does Helix BioPharma Corp. do?
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors;